Remove Contract Manufacturing Remove Drugs Remove Manufacturing
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

Insulin 328
article thumbnail

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organization

Pharma Mirror

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. As a result, some pharmaceutical companies are turning to third parties.

article thumbnail

Arranta Bio set to boost manufacturing for growing pipeline of microbiome drugs

Bio Pharma Dive

The contract manufacturer aims to capitalize on progress for microbiome-based therapies, a field that's been buoyed by some recent clinical successes.

article thumbnail

Contract manufacturer PCI pumps $365M+ into US, EU packaging projects

Fierce Pharma

Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both sides of the Atlantic. | Altogether, PCI’s manufacturing projects represent an investment of more than $365 million.

article thumbnail

Non-stop investment from CMOs and US Government into continuous manufacturing

Pharmaceutical Technology

In the last year, well-known contract manufacturing organisations (CMOs) such as Agilent Technologies (Santa Clara, California) and Abzena (Cambridge, UK) have expanded their continuous manufacturing capabilities. US Congress is also making substantial investments to improve the continuous manufacturing of pharmaceuticals.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.